Miniaturisation of multiple test sites on the biochip surface keeps sample and reagent volume to a minimum and automation of the test on a stand-alone instrument
Time is of the essence in myocardial infarction (MI) patients, as treatment for an MI has to be commenced within the first 12 hours of the acute event to be effective.
Biochip multi-markers have been shown to diagnose more myocardial infarctions within 12 hours of chest pain onset than current diagnostic practice These findings came from a study in a Dublin hospital where over 3000 blood samples were collected from 1100 patients over a three-year period.
The markers were assessed simultaneously using the revolutionary biochip array technology.
Evidence enables rapid integration into any clinical chemistry laboratory.
Troponin, the current gold standard for MI diagnosis, only rises six hours post event and the search for earlier MI markers has become more and more important, as the scope for treatment has advanced.
The cardiac multi-marker biochip, a combination of routine and novel markers, outperformed troponin by 20% in the 3-6 hour window and by 10% in the 6-12 hour bracket in diagnostic accuracy for identifying MI patients.
It also seems to have the ability for acute coronary syndrome (ACS) profiling and MI risk assessment.
Biochip array technology is already being utilised in laboratories around the world and provides a clinical solution and more holistic approach to diagnostics and treatment.
